A randomized controlled trial on the effectiveness of the abridged illness management and recovery program for people with schizophrenia spectrum disorders.

The results also showed a trend towards significance in exhibiting fewer psychopathological symptoms and greater motivation to achieve goals in experimental group than control group after completion of treatment as reflected in the measurement of Brief Psychiatric Rating Scale-Extended version (F = 3.76; p = .054; Cohen’s d = −.41) and Hope Scale Agency (F = 3.69; p = .06; Cohen’s d = .03) respectively.

also in 2,760 other papers